ERBB2 and non-small cell lung carcinoma: In addition, HER2‐directed ADCs such as trastuzumab deruxtecan are expanding into NSCLC, while TROP2‐targeted agents like datopotamab deruxtecan and novel EGFR‐directed ADCs are also under active investigation [48, 49, 52, 53].